Crohn’s Disease Clinical Trials | a Drug Pipeline Analysis Report 2023 | Companies – Centocor Ortho Biotech, UCB Biopharmaceuticals.

DelveInsight Business Research LLP
DelveInsight’s “Crohn’s Disease Pipeline Insights, 2023″ report by DelveInsight outlines comprehensive insights of the present clinical development scenario and growth prospects across the Crohn’s Disease market.

DelveInsight’s “Crohn’s Disease Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of the present clinical development scenario and growth prospects across the Crohn’s Disease market. A detailed picture of the Crohn’s Disease pipeline landscape is provided, which includes the disease overview and Crohn’s Disease treatment guidelines. 

Key Takeaways from the Crohn’s Disease Pipeline Report

Leading Crohn’s Disease companies developing novel drug candidates are Centocor Ortho Biotech, UCB Biopharmaceuticals, and others 

Promising Crohn’s Disease pipeline therapies in various stages of development include Adalimumab,  Infliximab, Certolizumab, and others.

Crohn’s Disease Overview

Inflammatory bowel disease (IBD) is an idiopathic disease caused by a dysregulated immune response to host intestinal microflora. It is a group of inflammatory conditions of the colon and small intestine. In IBD, the immune system responds incorrectly to environmental triggers, which causes inflammation of the gastrointestinal tract. The two major types of IBD are ulcerative colitis (UC), which is inflammation and sores (ulcers) along the superficial lining of the large intestine (colon) and rectum, and Crohn’s disease (CD), which involves inflammation of the lining of the digestive tract and can often involve the deeper layers of the digestive tract. The  CD is typically more severe than ulcerative colitis but is slightly less common. The disease can occur at any age, but CD is most often diagnosed in adolescents and adults between the ages of 20 and 30. There are different types of CD, each affecting different parts of the digestive tract including ileocolitis, ileitis, gastroduodenal Crohn’s disease, jejunoileitis, and Crohn’s colitis.

 Discover more about the emerging Crohn’s Disease drugs @ Crohn’s Disease Treatment Drugs

 Crohn’s Disease Pipeline Therapies and Key Companies

Centocor Ortho Biotech: Adalimumab

UCB Biopharmaceuticals: Infliximab

And  many others 

Scope of the Crohn’s Disease Pipeline Report 

Coverage: Global 

Key Crohn’s Disease  Companies: Centocor Ortho Biotech, UCB Biopharmaceuticals, and others 

Key Crohn’s Disease  Pipeline Therapies: Adalimumab,  Infliximab, and others.

Find out more about the Crohn’s Disease treatment options in development @ Crohn’s Disease Clinical Trials

Table of Contents

1. Introduction

2. Executive Summary

3. Overview

4. Pipeline Therapeutics

5. Late-Stage Products (Phase III)

6. Mid-Stage Products (Phase  II)

7. Early Stage Products (Phase  I/II)

8. Preclinical Stage Products

9. Discovery Stage Products

10. Therapeutic Assessment

11. Inactive Products

12. Collaborations Assessment- Licensing / Partnering / Funding

13. Unmet Needs

14. Market Drivers and Barriers

15. Appendix

16. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States

Daily Digest Signup

Daily business and market business news, business management tips, market research insights, and more.


Smart public opinion research for everyone.

%d bloggers like this: